tesaglitazar has been researched along with drf 2725 in 6 studies
| Studies (tesaglitazar) | Trials (tesaglitazar) | Recent Studies (post-2010) (tesaglitazar) | Studies (drf 2725) | Trials (drf 2725) | Recent Studies (post-2010) (drf 2725) |
|---|---|---|---|---|---|
| 74 | 13 | 25 | 41 | 3 | 4 |
| Protein | Taxonomy | tesaglitazar (IC50) | drf 2725 (IC50) |
|---|---|---|---|
| Chain A, peroxisome proliferator activated receptor gamma | Homo sapiens (human) | 0.092 | |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 0.092 | |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | 0.98 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deussen, HJ; Ebdrup, S; Fleckner, J; Frost Jensen, A; Mortensen, SB; Nygaard, L; Pettersson, I; Pridal, L; Rasmussen, HB; Sauerberg, P | 1 |
| Henke, BR | 1 |
| Kagechika, K; Kubo, H; Shibata, Y; Usui, H; Yamaguchi, M | 1 |
| Hashimoto, Y; Ishikawa, M; Makishima, M; Noguchi-Yachide, T; Okazaki, S; Shioi, R; Yamaguchi, T | 1 |
| Kaya, T; Sheu, SH; Vajda, S; Waxman, DJ | 1 |
| Farkouh, M; Plutzky, J; Rosenson, RS; Wright, RS | 1 |
2 review(s) available for tesaglitazar and drf 2725
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects.
Topics: Alkanesulfonates; Diabetic Angiopathies; Glycine; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Oxazines; Oxazoles; Phenylpropionates; Phosphorylation; PPAR alpha; PPAR delta; PPAR gamma; Thiazolidinediones; Thiophenes; United States; United States Food and Drug Administration | 2012 |
4 other study(ies) available for tesaglitazar and drf 2725
| Article | Year |
|---|---|
Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar.
Topics: Binding Sites; Crystallography, X-Ray; Hypoglycemic Agents; Ligands; Models, Molecular; Oxazines; Phenylpropionates; Radioligand Assay; Receptors, Cytoplasmic and Nuclear; Stereoisomerism; Transcription Factors | 2003 |
Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1).
Topics: Animals; Blood Glucose; Drug Design; Mice; PPAR alpha; PPAR gamma; Structure-Activity Relationship; Thiazolidinediones; Triglycerides; Weight Gain | 2012 |
Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
Topics: Acetamides; Binding Sites; Genes, Reporter; HEK293 Cells; Humans; Ligands; PPAR alpha; PPAR delta; Protein Binding; Stereoisomerism; Thiazolidinediones | 2017 |
Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping.
Topics: Alkanesulfonates; Binding Sites; Cinnamates; Computational Biology; Humans; Ligands; Oxazines; Oxazoles; Phenylpropionates; PPAR gamma; Protein Binding; Protein Conformation; Protein Interaction Mapping; Protein Structure, Tertiary; Rosiglitazone; Solvents; Thiazoles; Thiazolidinediones; Thiazolidines; Tyrosine | 2005 |